Suggested remit - To appraise the clinical and cost effectiveness of atezolizumab for untreated, locally advanced or metastatic, triple negative, PD-L1 positive breast cancer
 
 
Status In progress
Process STA 2018
ID number 1522

Provisional Schedule

Appraisal consultation 03 October 2019 - 24 October 2019
Committee meeting: 2 12 November 2019
Expected publication 05 February 2020

Project Team

Project lead Thomas Feist

Email enquiries

Evidence Review Group / Assessment Group Liverpool Reviews and Implementation Group, University of Liverpool

Consultees

Companies sponsors Roche
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Breast Cancer Care
  Breast Cancer Now
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
  UK Breast Cancer Group

Commentators

Comparator companies Pfizer
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety - Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
11 September 2019 Committee meeting: 1
14 January 2019 Invitation to participate
19 November 2018 - 17 December 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
31 July 2017 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance